Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $37,592 | $41,838 | $43,717 | $37,916 |
| G&A Expenses | $13,816 | $11,039 | $12,039 | $13,070 |
| SG&A Expenses | $13,816 | $11,039 | $12,039 | $13,070 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51,408 | $52,877 | $55,756 | $50,986 |
| Operating Income | $0 | -$52,877 | -$55,756 | -$50,986 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $9,875 | $8,258 | $3,366 |
| Pre-Tax Income | $0 | -$43,002 | -$47,498 | -$47,620 |
| Tax Expense | $0 | $0 | $7 | $358 |
| Net Income | $0 | -$43,002 | -$47,505 | -$47,978 |
| % Margin | – | – | – | – |
| EPS | -0.54 | -0.52 | -0.6 | -0.62 |
| % Growth | -3.8% | 13.3% | 3.2% | – |
| EPS Diluted | -0.54 | -0.52 | -0.6 | -0.62 |
| Weighted Avg Shares Out | 85,289 | 83,468 | 79,788 | 76,910 |
| Weighted Avg Shares Out Dil | 85,289 | 83,468 | 79,788 | 76,910 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7,320 | $6,519 | $947 |
| Interest Expense | $0 | $0 | $964 | $947 |
| Depreciation & Amortization | $0 | $50,586 | -$2,718 | -$3,323 |
| EBITDA | $0 | $5,293 | -$55,756 | -$50,942 |
| % Margin | – | – | – | – |